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ABSTRACT  
Background. Machado-Joseph disease (MJD) is an autosomal dominant 
neurodegenerative disorder of late onset, caused by a (CAG)n expansion at the ATXN3 
gene (14q32.1). Variation in age-at-onset is partially explained by the size of the (CAG)n 
tract in expanded alleles. The remaining variation should be the product of other factors, 
namely modifier genes. The genotype at the APOE locus has been described as a possible 
modifier in different neurological disorders, namely Parkinson (PD) and Huntington 
disease (HD). In the CNS, apolipoprotein E constitutes an important mediator of 
cholesterol transport/metabolism, which is essential for synaptic integrity and neuronal 
function. 
Objective. To investigate a modulating effect of the APOE polymorphism on age-
at-onset of MJD. 
Design and Subjects. The APOE polymorphism was typed in a series of 192 MJD 
patients. 
Results. Cases with the ε2/ε3 genotype presented an earlier onset, when compared 
with those with ε3/ε3 or ε3/ε4. In this series of patients, the presence of an APOE ε2 allele 
implies a decrease of nearly 5 years in the age-at-onset. When combining, in a general 
linear model, several other predictors, namely the presence/absence of the APOE ε2 
allele, with the size of the (CAG)n in expanded alleles, the model was significantly 
improved and the explanation of onset variance was raised from 59.8% to 66.5%.  
Furthermore, the presence of the ε2 allele was associated with an onset below 39 years 
(OR=5.00; 95% CI: 1.18-21.14). 
Conclusions. These findings indicate that the polymorphism at the APOE gene 
plays a role as a genetic modifier of MJD phenotype.  
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INTRODUCTION  
Machado-Joseph disease (MJD), also known as spinocerebellar ataxia type 3 
(SCA3), is an autosomal dominant neurodegenerative disorder of late onset, caused by an 
expansion of a (CAG)n in the coding region of ATXN3 (14q32.1), encoding for ataxin-3.
1, 
2
 MJD is the most frequent type of SCA,
3
 and reaches its highest worldwide value of 
prevalence in the Azores islands (Portugal).
4
 Wild-type ATXN3 alleles comprise 12 to 44 
CAG repeats, whereas expanded alleles consensually have more than 52 repeat units.
5, 6
 
MJD presents clinical heterogeneity, namely on what concerns the age-at-onset, with a 
mean around 40 years, but with extremes of 4
7
 to 70 years.
8
 Variation in the age-at-onset 
is only partially explained (~50-75%)
9, 10
 by the size of the (CAG)n tract in the expanded 
ATXN3 alleles. Familial factors may explain additional variance in age-at-onset,
11, 12
 
indicating that modifier genes may play a role. The hypothesis that other CAG-containing 
proteins could interact with the expanded ataxin-3 and influence the MJD onset was 
raised.
13, 14
 An association between severity of fasciculations (minor signs in MJD) and 
the CAG length of the large SCA2 allele was found,
14
 but no influence on disease onset 
was detected.  
Apolipoprotein E (apoE) is an ubiquitous protein involved in lipid storage, 
transport, and metabolism.
15
 APOE (19q13.2) has three main alleles (ɛ2, ɛ3, and ɛ4), 
encoding for isoforms E2, E3 and E4 (which differ at positions 112 and 158).
16, 17
 These 
differences alter the protein’s structure, influencing association with lipids and its binding 
to the receptors. While apoE3 and E4 bind to Low-Density Lipoprotein Receptors 
(LDLR) with similarly high affinity, apoE2 has a 50-100-fold weaker affinity.
18, 19
 In 
CNS, ApoE is secreted by astrocytes, and is highly expressed in both intracellular and 
extracellular spaces,
20
 constituting an important mediator of cholesterol and lipid 
transport in the brain (for a review see
21
), specially of cholesterol transport from 
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astrocytes to neurons; furthermore, it has been suggested that apoE isoforms differentially 
regulate synaptic plasticity and repair.
22
 
The APOE ɛ4 allele has been consistently associated, for example, with increased 
risk (e.g.
23, 24
) and a lower onset in sporadic Alzheimer disease (AD),
24
 increased risk of 
cognitive impairment,
25, 26
 as well as with a more unfavorable outcome after traumatic 
brain injury.
27, 28
 On the other hand, the ɛ2 allele has been associated with a higher 
prevalence
29
 and earlier onset of sporadic PD,
30, 31
 increased risk of frontotemporal 
dementia (FTD),
32
 and an earlier onset in HD.
33
  
The main goal of this work was to investigate a modulating effect of APOE on MJD 
phenotype.  
 
METHODS 
Blood samples from 192 MJD patients (59 from the Azores, 73 from mainland 
Portugal and 60 from Brazil) were collected after informed consent. DNA was extracted 
from all samples using standard procedures. The size of the (CAG)n tract was determined 
following a methodology previously reported,
34
 and the APOE polymorphism was typed 
according to previously described conditions.
35
 For the total series of patients, data on the 
age-at-onset was collected as close as possible from the first complaints of gait instability 
or diplopia (the two most consistent initial symptoms in SCA3/MJD, according to the 
extensive study by Coutinho
8
). Patients with several years of disease progression were 
asked for the age-at-onset of the mentioned symptoms. The age reported by them was 
confronted with the one stated by their close relatives (usually caregivers) and, whenever 
possible, additional information from previous records was also taken into account, in 
order to get an onset as accurate as possible.   
5 
 
Conformity with the Hardy-Weinberg equilibrium was tested using the exact 
probability without bias. An exact test of differentiation evaluated differences in APOE 
genotypic frequencies among the three groups of patients, as well as between the patients’ 
groups and the corresponding populations of origin (previously published for the 
populations of Azores,
35
 mainland Portugal
36, 37
 and Brazil
38, 39
). All analyses were 
performed using the Arlequin package.
40
 
Age-at-onset for the three most frequent APOE genotypes was adjusted for the 
mean number of CAGs in the expanded ATXN3 allele, after fitting a linear regression 
model. Differences in the adjusted age-at-onset between APOE genotypes were analyzed 
using the t-test calculator of OpenEpi v.2.3.1 (www.openepi.com). Multivariate linear 
regression analyses were used to test the effect of several variables on age-at-onset: 
CAGs in expanded and normal alleles, presence/absence of the APOE ε2 allele, 
population of origin, and gender. To account for kinship among some patients of the 
Azorean series, a generalized estimating equation model was also applied. The risk of 
developing MJD before 39 years of age (mean for the present series) among patients with 
APOE ε2 allele was estimated as an odds ratio (OR), using logistic regression analysis, 
with onset < 39 yr vs. ≥ 39 yr as the dependent variable. All analyses were performed 
using SPSS v. 15.0.
41
 
 
RESULTS 
The APOE genotypic frequencies were in conformity with Hardy-Weinberg 
expectations. No significant differences were detected in the genotypic frequencies 
among groups of patients (Azores, mainland Portugal or Brazil), nor between the patients’ 
groups and the corresponding populations of origin.   
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A summary of descriptive statistics, for the MJD patients studied, is shown in Table 
1. Adjusting onset for the (CAG)n size, patients with the ε2/ε3 genotype had an earlier 
onset than the other two groups (Table 1). This difference was statistically significant 
between ε2/ε3 and ε3/ε3 (t-test; p=0.024), but did not reach statistical significance 
between ε2/ε3 and ε3/ε4 (t-test; p=0.097).  
The (CAG)n size in the expanded ATXN3 alleles is known to be inversely correlated 
with the age-at-onset of MJD (present series: r =–0.769; p<0.001). Given the earlier onset 
observed for APOE ε2/ε3 genotype, the presence/absence of the APOE ε2 allele was 
tested, in a general linear model, in addition to the (CAG)n size in expanded alleles. When 
the APOE ε2 status was taken into account (given the impossibility to dissociate the effect 
of ε2 from ε4, the three patients with ε2/ε4 genotype were excluded), the percentage of 
explanation of the onset variance was significantly increased from 59.8% to 60.9% 
(F=6.46; p=0.012). In this series of patients, the presence of APOE ε2 decreases the onset 
age by nearly 5 years. When adding the number of CAGs in normal ATXN3 alleles, the 
model was not significantly improved; however, the population background (Azores, 
mainland Portugal and Brazil) (F=19.51; p<0.001) and gender of patients (F=8.26; 
p=0.005) majored the outcome of APOE ε2 (F=8.71; p=0.004), improving onset variance 
explanation to 66.5%. Even taking into account the fact that the subseries of patients from 
the Azores contained related patients, the effect of APOE ε2 was still statistically 
significant (Wald Chi-Square=7.12; p=0.008). When patients were divided according to 
onset mean (< 39 yr vs. ≥ 39 yr), an association was found between the presence of ε2 
allele and an earlier onset (OR=5.00; 95% CI: 1.18-21.14).  
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COMMENT 
The present results indicate that the APOE ε2 allele influences the MJD phenotype, 
increasing the risk for earlier onset. When the ε2 allele status was accounted (additionally 
to the CAG repeat size in expanded alleles), an apparent discrepancy between the 
approximately five years earlier onset in ε2 carriers and the minimal (but statistically 
significant) improvement of only about 1% in the explanation of onset variance was 
detected. This observation is probably due to the fact that the number of patients with the 
ε2 allele is not very large (n = 20). Notwithstanding, in our series of patients, the risk of 
developing MJD before 39 years is five times higher in carriers of the ε2 allele in 
comparison with the non-carriers.  
The APOE ε4 is associated with an increased risk for AD, while the ε2 allele may 
be protective.
23
 In contrast, having at least one copy of ε4 may protect against age-related 
macular degeneration or delay vision loss, while having at least one copy of ε2 may 
increase the risk for this disease or for an earlier onset.
42, 43
 The APOE ε2 allele has been 
also associated with an earlier onset of PD
30, 31
 and HD.
33
 This is in agreement with the 
effect we now observed in MJD. Some MJD patients may present a PD-like phenotype,
44-
46
 which may indicate a shared neuropathological mechanism. In HD, the influence of the 
APOE genotype is still controversial (e.g.
33, 47
); nevertheless, in agreement with our 
results, Kehoe and co-workers
33
 found that male patients with the ε2/ε3 genotype had an 
earlier onset than those with other APOE genotypes. In face of the present results, and 
taking into account the postulated differential efficiency of different apoE isoforms in 
cholesterol transport, it can be hypothesized that apoE2 may be less efficient, leading to 
an earlier neuronal damage and MJD onset.  
Rapp et al.,
48
 using the rat as a model, have postulated that neurons and astrocytes 
express different apoE receptors. Astrocytes express preferentially the LDLR, in contrast 
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with neurons, where the principal receptor is LRP (LDL receptor-related protein). In 
hippocampal astrocytes, the efficiency of apoE3 and apoE4 mediated cholesterol uptake 
is similar, whereas it is reduced for apoE2. This low affinity of apoE2 for LDLR in 
astrocytes could contribute to the altered homeostasis of cholesterol in the brain, which 
may ultimately be associated with the earlier manifestation of MJD in ε2 carriers. 
These results support a role of APOE as modulator of MJD phenotypic variability, 
in addition to the known effect of the CAG tract size in the expanded allele.   
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Table 1: Descriptive statistics for the MJD patients studied 
Characteristics 
APOE Genotype 
Total 
ε2/ ε3 ε3/ ε3 ε3/ ε4 ε2/ ε4 ε4/ ε4 
Number of patients (%) 
Population 
Portugal 
Azores 
Mainland 
Brazil 
Gender 
Male 
Female 
20 (10.4) 
 
 
6 (10.2) 
9 (12.3) 
5 (8.3) 
 
10 (10.3) 
10 (10.5) 
134 (69.8) 
 
 
42 (71.2) 
52 (71.2) 
40 (66.7) 
 
71 (73.2) 
63 (66.3) 
33 (17.2) 
 
 
11 (18.6) 
11 (15.1) 
11 (18.3) 
 
13 (13.4) 
20 (21.1) 
3 (1.6) 
 
 
0 (0.0) 
1 (1.4) 
2 (3.3) 
 
2 (2.1) 
1 (1.1) 
2 (1.0) 
 
 
0 (0.0) 
0 (0.0) 
2 (3.3) 
 
1 (1.0) 
1 (1.1) 
192 
 
 
59 
73 
60 
 
97 
95 
Age at onset 
Mean, yr ± SE 
Adjusted onset*, yr ± SE 
Range, yr 
 
36.95 ± 2.83 
34.74 ± 2.27 
21-60 
 
39.30 ± 1.09 
39.16 ± 0.67 
12-70 
 
37.70 ± 1.84 
39.08 ± 1.11 
12-58 
 
33.33± 10.93 
--- 
20-55 
 
36.50 ± 16.50 
--- 
20-53 
 
38.66 ± 0.90 
--- 
12-70 
CAG repeat length 
Normal 
Mean ± SE 
Range 
Expanded 
Mean ± SE 
Range 
 
 
23.45 ± 1.02 
14-34 
 
71.85 ± 0.80 
65-77 
 
 
21.92 ± 0.41 
14-32 
 
72.75 ± 0.34 
63-82 
 
 
21.82 ± 0.94 
14-37 
 
73.30 ± 0.54 
69-80 
 
 
15.67 ± 1.67 
14-19 
 
74.00 ± 1.53 
72-77 
 
 
26.00 ± 3.00 
23-29 
 
75.50 ± 3.50 
72-79 
 
 
22.01 ± 0.35 
14-37 
 
72.80 ± 0.27 
63-82 
*Adjusted for the mean size of expanded CAG repeats in the patient sample. 
